nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.21	0.5	CiPCiCtD
Afatinib—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.21	0.5	CiPCiCtD
Afatinib—LCK—hematologic cancer	0.108	0.567	CbGaD
Afatinib—ABL1—hematologic cancer	0.0507	0.266	CbGaD
Afatinib—PHKG2—Ruxolitinib—hematologic cancer	0.0293	0.123	CbGbCtD
Afatinib—DYRK1A—Ruxolitinib—hematologic cancer	0.0293	0.123	CbGbCtD
Afatinib—ABCG2—hematologic cancer	0.0225	0.118	CbGaD
Afatinib—IRAK1—Ruxolitinib—hematologic cancer	0.0168	0.0706	CbGbCtD
Afatinib—HIPK4—Imatinib—hematologic cancer	0.0158	0.0663	CbGbCtD
Afatinib—BLK—Nilotinib—hematologic cancer	0.0144	0.0603	CbGbCtD
Afatinib—EPHA6—Nilotinib—hematologic cancer	0.0144	0.0603	CbGbCtD
Afatinib—LCK—Imatinib—hematologic cancer	0.0129	0.0542	CbGbCtD
Afatinib—BLK—Dasatinib—hematologic cancer	0.0127	0.0533	CbGbCtD
Afatinib—LCK—Nilotinib—hematologic cancer	0.0117	0.0493	CbGbCtD
Afatinib—LCK—Dasatinib—hematologic cancer	0.0104	0.0436	CbGbCtD
Afatinib—ABL1—Imatinib—hematologic cancer	0.0103	0.0431	CbGbCtD
Afatinib—ABCB1—hematologic cancer	0.00938	0.0491	CbGaD
Afatinib—ABL1—Nilotinib—hematologic cancer	0.00933	0.0392	CbGbCtD
Afatinib—ABL1—Dasatinib—hematologic cancer	0.00825	0.0346	CbGbCtD
Afatinib—ABCG2—Clofarabine—hematologic cancer	0.00522	0.0219	CbGbCtD
Afatinib—ABCG2—Daunorubicin—hematologic cancer	0.00306	0.0128	CbGbCtD
Afatinib—ABCG2—Teniposide—hematologic cancer	0.00266	0.0112	CbGbCtD
Afatinib—ABCG2—Cladribine—hematologic cancer	0.00255	0.0107	CbGbCtD
Afatinib—ABCG2—Imatinib—hematologic cancer	0.00234	0.00984	CbGbCtD
Afatinib—ABCG2—Nilotinib—hematologic cancer	0.00213	0.00894	CbGbCtD
Afatinib—ABCG2—Dasatinib—hematologic cancer	0.00188	0.0079	CbGbCtD
Afatinib—ABCB1—Lenalidomide—hematologic cancer	0.00188	0.0079	CbGbCtD
Afatinib—ABCG2—Mitoxantrone—hematologic cancer	0.00186	0.00781	CbGbCtD
Afatinib—ABCG2—Irinotecan—hematologic cancer	0.00146	0.00615	CbGbCtD
Afatinib—ABCG2—Vincristine—hematologic cancer	0.00128	0.00537	CbGbCtD
Afatinib—ABCG2—Cisplatin—hematologic cancer	0.00119	0.00501	CbGbCtD
Afatinib—ABCG2—Etoposide—hematologic cancer	0.00117	0.00492	CbGbCtD
Afatinib—BLK—hematopoietic system—hematologic cancer	0.00112	0.0546	CbGeAlD
Afatinib—ABCB1—Daunorubicin—hematologic cancer	0.0011	0.00463	CbGbCtD
Afatinib—ABCB1—Alitretinoin—hematologic cancer	0.00108	0.00454	CbGbCtD
Afatinib—ABCG2—Dexamethasone—hematologic cancer	0.000965	0.00405	CbGbCtD
Afatinib—HIPK4—gonad—hematologic cancer	0.000854	0.0416	CbGeAlD
Afatinib—ABCB1—Imatinib—hematologic cancer	0.000846	0.00355	CbGbCtD
Afatinib—ABCG2—Doxorubicin—hematologic cancer	0.0008	0.00336	CbGbCtD
Afatinib—ABCG2—Methotrexate—hematologic cancer	0.000775	0.00325	CbGbCtD
Afatinib—ERBB2—hematopoietic system—hematologic cancer	0.00077	0.0375	CbGeAlD
Afatinib—ABCB1—Nilotinib—hematologic cancer	0.000768	0.00322	CbGbCtD
Afatinib—ABCB1—Vinorelbine—hematologic cancer	0.000762	0.0032	CbGbCtD
Afatinib—BLK—blood—hematologic cancer	0.000745	0.0362	CbGeAlD
Afatinib—DYRK1A—hematopoietic system—hematologic cancer	0.000741	0.0361	CbGeAlD
Afatinib—ABCB1—Dasatinib—hematologic cancer	0.000679	0.00285	CbGbCtD
Afatinib—EPHA6—gonad—hematologic cancer	0.000675	0.0328	CbGeAlD
Afatinib—ABCB1—Mitoxantrone—hematologic cancer	0.000671	0.00282	CbGbCtD
Afatinib—PHKG2—gonad—hematologic cancer	0.000651	0.0317	CbGeAlD
Afatinib—HIPK4—testis—hematologic cancer	0.000616	0.0299	CbGeAlD
Afatinib—ABCB1—Betamethasone—hematologic cancer	0.000598	0.00251	CbGbCtD
Afatinib—ABCB1—Gemcitabine—hematologic cancer	0.000593	0.00249	CbGbCtD
Afatinib—ABCB1—Prednisolone—hematologic cancer	0.00059	0.00248	CbGbCtD
Afatinib—ERBB2—gonad—hematologic cancer	0.000586	0.0285	CbGeAlD
Afatinib—IRAK1—hematopoietic system—hematologic cancer	0.000576	0.028	CbGeAlD
Afatinib—DYRK1A—gonad—hematologic cancer	0.000564	0.0274	CbGeAlD
Afatinib—ABCB1—Prednisone—hematologic cancer	0.000557	0.00234	CbGbCtD
Afatinib—ABCB1—Irinotecan—hematologic cancer	0.000528	0.00222	CbGbCtD
Afatinib—ERBB2—blood—hematologic cancer	0.00051	0.0248	CbGeAlD
Afatinib—PHKG2—lung—hematologic cancer	0.000498	0.0242	CbGeAlD
Afatinib—EPHA6—testis—hematologic cancer	0.000487	0.0237	CbGeAlD
Afatinib—ABCB1—Vinblastine—hematologic cancer	0.00047	0.00197	CbGbCtD
Afatinib—PHKG2—testis—hematologic cancer	0.000469	0.0228	CbGeAlD
Afatinib—ABCB1—Vincristine—hematologic cancer	0.000462	0.00194	CbGbCtD
Afatinib—ERBB2—lung—hematologic cancer	0.000447	0.0218	CbGeAlD
Afatinib—ERBB4—lung—hematologic cancer	0.000447	0.0218	CbGeAlD
Afatinib—BLK—lymph node—hematologic cancer	0.000446	0.0217	CbGeAlD
Afatinib—DYRK1A—lung—hematologic cancer	0.000431	0.0209	CbGeAlD
Afatinib—ABCB1—Cisplatin—hematologic cancer	0.000431	0.00181	CbGbCtD
Afatinib—ABCB1—Etoposide—hematologic cancer	0.000423	0.00178	CbGbCtD
Afatinib—ERBB2—testis—hematologic cancer	0.000422	0.0205	CbGeAlD
Afatinib—ERBB4—testis—hematologic cancer	0.000422	0.0205	CbGeAlD
Afatinib—DYRK1A—testis—hematologic cancer	0.000406	0.0198	CbGeAlD
Afatinib—IRAK1—blood—hematologic cancer	0.000382	0.0186	CbGeAlD
Afatinib—EGFR—lung—hematologic cancer	0.000379	0.0184	CbGeAlD
Afatinib—LCK—blood—hematologic cancer	0.000372	0.0181	CbGeAlD
Afatinib—IRAK1—bone marrow—hematologic cancer	0.000369	0.018	CbGeAlD
Afatinib—LCK—bone marrow—hematologic cancer	0.00036	0.0175	CbGeAlD
Afatinib—EGFR—testis—hematologic cancer	0.000358	0.0174	CbGeAlD
Afatinib—ABCB1—Dexamethasone—hematologic cancer	0.000348	0.00146	CbGbCtD
Afatinib—PHKG2—lymph node—hematologic cancer	0.00034	0.0165	CbGeAlD
Afatinib—IRAK1—lung—hematologic cancer	0.000335	0.0163	CbGeAlD
Afatinib—LCK—lung—hematologic cancer	0.000326	0.0159	CbGeAlD
Afatinib—ABL1—hematopoietic system—hematologic cancer	0.000323	0.0157	CbGeAlD
Afatinib—IRAK1—testis—hematologic cancer	0.000316	0.0154	CbGeAlD
Afatinib—LCK—testis—hematologic cancer	0.000308	0.015	CbGeAlD
Afatinib—ERBB2—lymph node—hematologic cancer	0.000306	0.0149	CbGeAlD
Afatinib—Vandetanib—FLT3—hematologic cancer	0.000295	0.161	CrCbGaD
Afatinib—DYRK1A—lymph node—hematologic cancer	0.000295	0.0143	CbGeAlD
Afatinib—ABCB1—Doxorubicin—hematologic cancer	0.000289	0.00121	CbGbCtD
Afatinib—ABCB1—Methotrexate—hematologic cancer	0.000279	0.00117	CbGbCtD
Afatinib—Vandetanib—ABL2—hematologic cancer	0.000263	0.144	CrCbGaD
Afatinib—EGFR—lymph node—hematologic cancer	0.000259	0.0126	CbGeAlD
Afatinib—Vandetanib—LCK—hematologic cancer	0.000251	0.137	CrCbGaD
Afatinib—ABL1—gonad—hematologic cancer	0.000245	0.0119	CbGeAlD
Afatinib—IRAK1—lymph node—hematologic cancer	0.000229	0.0111	CbGeAlD
Afatinib—Vandetanib—FGR—hematologic cancer	0.000223	0.122	CrCbGaD
Afatinib—LCK—lymph node—hematologic cancer	0.000223	0.0109	CbGeAlD
Afatinib—ABL1—blood—hematologic cancer	0.000214	0.0104	CbGeAlD
Afatinib—ABL1—bone marrow—hematologic cancer	0.000207	0.0101	CbGeAlD
Afatinib—Vandetanib—RET—hematologic cancer	0.00019	0.104	CrCbGaD
Afatinib—ABL1—lung—hematologic cancer	0.000187	0.00911	CbGeAlD
Afatinib—ABL1—testis—hematologic cancer	0.000177	0.0086	CbGeAlD
Afatinib—ABCG2—blood—hematologic cancer	0.000135	0.00656	CbGeAlD
Afatinib—Vandetanib—PDGFRB—hematologic cancer	0.000132	0.072	CrCbGaD
Afatinib—ABCG2—bone marrow—hematologic cancer	0.00013	0.00634	CbGeAlD
Afatinib—ABL1—lymph node—hematologic cancer	0.000128	0.00623	CbGeAlD
Afatinib—ABCG2—lung—hematologic cancer	0.000118	0.00575	CbGeAlD
Afatinib—Vandetanib—ABL1—hematologic cancer	0.000117	0.0642	CrCbGaD
Afatinib—ABCG2—testis—hematologic cancer	0.000112	0.00542	CbGeAlD
Afatinib—Vandetanib—SRC—hematologic cancer	0.000106	0.0581	CrCbGaD
Afatinib—ABCB1—hematopoietic system—hematologic cancer	0.0001	0.00488	CbGeAlD
Afatinib—DYRK1A—Topotecan—Irinotecan—hematologic cancer	8.51e-05	0.0577	CbGdCrCtD
Afatinib—Vandetanib—VEGFA—hematologic cancer	8.46e-05	0.0463	CrCbGaD
Afatinib—ABCG2—lymph node—hematologic cancer	8.08e-05	0.00393	CbGeAlD
Afatinib—ERBB2—Ribavirin—Clofarabine—hematologic cancer	7.95e-05	0.0539	CbGdCrCtD
Afatinib—ABCB1—gonad—hematologic cancer	7.63e-05	0.00371	CbGeAlD
Afatinib—ERBB2—Ribavirin—Nelarabine—hematologic cancer	7.47e-05	0.0507	CbGdCrCtD
Afatinib—ABCB1—blood—hematologic cancer	6.65e-05	0.00323	CbGeAlD
Afatinib—ERBB2—Topotecan—Irinotecan—hematologic cancer	6.55e-05	0.0444	CbGdCrCtD
Afatinib—ABCB1—bone marrow—hematologic cancer	6.43e-05	0.00313	CbGeAlD
Afatinib—ERBB2—Ribavirin—Fludarabine—hematologic cancer	5.83e-05	0.0396	CbGdCrCtD
Afatinib—ABCB1—lung—hematologic cancer	5.83e-05	0.00283	CbGeAlD
Afatinib—DYRK1A—Doxorubicin—Daunorubicin—hematologic cancer	5.75e-05	0.039	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Daunorubicin—hematologic cancer	5.75e-05	0.039	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Daunorubicin—hematologic cancer	5.75e-05	0.039	CbGdCrCtD
Afatinib—ERBB2—Ribavirin—Cytarabine—hematologic cancer	5.51e-05	0.0374	CbGdCrCtD
Afatinib—ABCB1—testis—hematologic cancer	5.5e-05	0.00267	CbGeAlD
Afatinib—Vandetanib—ABCG2—hematologic cancer	5.21e-05	0.0285	CrCbGaD
Afatinib—ERBB2—Podofilox—Teniposide—hematologic cancer	4.96e-05	0.0336	CbGdCrCtD
Afatinib—Gefitinib—ABCG2—hematologic cancer	4.95e-05	0.0271	CrCbGaD
Afatinib—ABL1—Topotecan—Irinotecan—hematologic cancer	4.89e-05	0.0331	CbGdCrCtD
Afatinib—ERBB2—Doxorubicin—Daunorubicin—hematologic cancer	4.42e-05	0.03	CbGdCrCtD
Afatinib—ERBB2—Epirubicin—Daunorubicin—hematologic cancer	4.42e-05	0.03	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Idarubicin—hematologic cancer	4.36e-05	0.0295	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Idarubicin—hematologic cancer	4.36e-05	0.0295	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Idarubicin—hematologic cancer	4.36e-05	0.0295	CbGdCrCtD
Afatinib—ABCB1—lymph node—hematologic cancer	3.99e-05	0.00194	CbGeAlD
Afatinib—ERBB2—Doxorubicin—Idarubicin—hematologic cancer	3.35e-05	0.0227	CbGdCrCtD
Afatinib—ERBB2—Epirubicin—Idarubicin—hematologic cancer	3.35e-05	0.0227	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	3.3e-05	0.0224	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	3.3e-05	0.0224	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	3.3e-05	0.0224	CbGdCrCtD
Afatinib—ERBB2—Podofilox—Etoposide—hematologic cancer	2.95e-05	0.02	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	2.5e-05	0.017	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	2.5e-05	0.017	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Idarubicin—hematologic cancer	2.5e-05	0.017	CbGdCrCtD
Afatinib—Vandetanib—ALB—hematologic cancer	2.27e-05	0.0124	CrCbGaD
Afatinib—Gefitinib—ALB—hematologic cancer	2.16e-05	0.0118	CrCbGaD
Afatinib—Gefitinib—ABCB1—hematologic cancer	2.06e-05	0.0113	CrCbGaD
Afatinib—DYRK1A—Idarubicin—Epirubicin—hematologic cancer	2e-05	0.0136	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—hematologic cancer	2e-05	0.0136	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—hematologic cancer	2e-05	0.0136	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—hematologic cancer	1.85e-05	0.0126	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—hematologic cancer	1.85e-05	0.0126	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—hematologic cancer	1.85e-05	0.0126	CbGdCrCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—hematologic cancer	1.54e-05	0.0104	CbGdCrCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—hematologic cancer	1.42e-05	0.00966	CbGdCrCtD
Afatinib—ERBB2—Exemestane—Prednisone—hematologic cancer	1.22e-05	0.00826	CbGdCrCtD
Afatinib—Vomiting—Thalidomide—hematologic cancer	1.21e-05	0.000193	CcSEcCtD
Afatinib—Dizziness—Carmustine—hematologic cancer	1.21e-05	0.000193	CcSEcCtD
Afatinib—Constipation—Etoposide—hematologic cancer	1.21e-05	0.000193	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—hematologic cancer	1.21e-05	0.000193	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—hematologic cancer	1.21e-05	0.000193	CcSEcCtD
Afatinib—Rash—Thalidomide—hematologic cancer	1.2e-05	0.000191	CcSEcCtD
Afatinib—Dermatitis—Thalidomide—hematologic cancer	1.2e-05	0.000191	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—hematologic cancer	1.2e-05	0.000191	CcSEcCtD
Afatinib—Dizziness—Alitretinoin—hematologic cancer	1.2e-05	0.000191	CcSEcCtD
Afatinib—Diarrhoea—Vincristine—hematologic cancer	1.19e-05	0.000191	CcSEcCtD
Afatinib—Headache—Thalidomide—hematologic cancer	1.19e-05	0.00019	CcSEcCtD
Afatinib—ERBB2—Exemestane—Prednisolone—hematologic cancer	1.19e-05	0.00806	CbGdCrCtD
Afatinib—Asthenia—Gemcitabine—hematologic cancer	1.19e-05	0.00019	CcSEcCtD
Afatinib—Dizziness—Ifosfamide—hematologic cancer	1.18e-05	0.000189	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—hematologic cancer	1.18e-05	0.000188	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—hematologic cancer	1.17e-05	0.000187	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—hematologic cancer	1.17e-05	0.000187	CcSEcCtD
Afatinib—Pruritus—Gemcitabine—hematologic cancer	1.17e-05	0.000187	CcSEcCtD
Afatinib—Nausea—Thiotepa—hematologic cancer	1.17e-05	0.000187	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—hematologic cancer	1.17e-05	0.000186	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—hematologic cancer	1.17e-05	0.000186	CcSEcCtD
Afatinib—Diarrhoea—Irinotecan—hematologic cancer	1.16e-05	0.000186	CcSEcCtD
Afatinib—Diarrhoea—Mitoxantrone—hematologic cancer	1.16e-05	0.000186	CcSEcCtD
Afatinib—Vomiting—Carmustine—hematologic cancer	1.16e-05	0.000185	CcSEcCtD
Afatinib—Insomnia—Triamcinolone—hematologic cancer	1.16e-05	0.000185	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—hematologic cancer	1.16e-05	0.000184	CcSEcCtD
Afatinib—Infection—Betamethasone—hematologic cancer	1.16e-05	0.000184	CcSEcCtD
Afatinib—Infection—Dexamethasone—hematologic cancer	1.16e-05	0.000184	CcSEcCtD
Afatinib—Dizziness—Vincristine—hematologic cancer	1.15e-05	0.000184	CcSEcCtD
Afatinib—Rash—Carmustine—hematologic cancer	1.15e-05	0.000184	CcSEcCtD
Afatinib—Dermatitis—Carmustine—hematologic cancer	1.15e-05	0.000184	CcSEcCtD
Afatinib—Vomiting—Alitretinoin—hematologic cancer	1.15e-05	0.000184	CcSEcCtD
Afatinib—Infestation—Doxorubicin—hematologic cancer	1.15e-05	0.000183	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—hematologic cancer	1.15e-05	0.000183	CcSEcCtD
Afatinib—ABL1—Idarubicin—Epirubicin—hematologic cancer	1.15e-05	0.00779	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	1.15e-05	0.00779	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	1.15e-05	0.00779	CbGdCrCtD
Afatinib—Headache—Carmustine—hematologic cancer	1.14e-05	0.000183	CcSEcCtD
Afatinib—Dyspnoea—Triamcinolone—hematologic cancer	1.14e-05	0.000182	CcSEcCtD
Afatinib—Rash—Alitretinoin—hematologic cancer	1.14e-05	0.000182	CcSEcCtD
Afatinib—Nervous system disorder—Betamethasone—hematologic cancer	1.14e-05	0.000182	CcSEcCtD
Afatinib—Nervous system disorder—Dexamethasone—hematologic cancer	1.14e-05	0.000182	CcSEcCtD
Afatinib—Dermatitis—Alitretinoin—hematologic cancer	1.14e-05	0.000182	CcSEcCtD
Afatinib—Vomiting—Ifosfamide—hematologic cancer	1.14e-05	0.000182	CcSEcCtD
Afatinib—Headache—Alitretinoin—hematologic cancer	1.13e-05	0.000181	CcSEcCtD
Afatinib—Diarrhoea—Gemcitabine—hematologic cancer	1.13e-05	0.000181	CcSEcCtD
Afatinib—Nausea—Thalidomide—hematologic cancer	1.13e-05	0.00018	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—hematologic cancer	1.13e-05	0.00018	CcSEcCtD
Afatinib—Dyspepsia—Triamcinolone—hematologic cancer	1.13e-05	0.00018	CcSEcCtD
Afatinib—Rash—Ifosfamide—hematologic cancer	1.13e-05	0.00018	CcSEcCtD
Afatinib—Dermatitis—Ifosfamide—hematologic cancer	1.13e-05	0.00018	CcSEcCtD
Afatinib—Dizziness—Irinotecan—hematologic cancer	1.12e-05	0.000179	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—hematologic cancer	1.12e-05	0.000179	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—hematologic cancer	1.12e-05	0.000178	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—hematologic cancer	1.12e-05	0.000178	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—hematologic cancer	1.12e-05	0.000178	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—hematologic cancer	1.11e-05	0.000178	CcSEcCtD
Afatinib—Vomiting—Vincristine—hematologic cancer	1.11e-05	0.000177	CcSEcCtD
Afatinib—Asthenia—Cisplatin—hematologic cancer	1.11e-05	0.000177	CcSEcCtD
Afatinib—Fatigue—Triamcinolone—hematologic cancer	1.11e-05	0.000176	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—hematologic cancer	1.1e-05	0.000176	CcSEcCtD
Afatinib—Rash—Vincristine—hematologic cancer	1.1e-05	0.000176	CcSEcCtD
Afatinib—Dermatitis—Vincristine—hematologic cancer	1.1e-05	0.000175	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—hematologic cancer	1.1e-05	0.000175	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—hematologic cancer	1.09e-05	0.000174	CcSEcCtD
Afatinib—Headache—Vincristine—hematologic cancer	1.09e-05	0.000174	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—hematologic cancer	1.09e-05	0.000173	CcSEcCtD
Afatinib—Nausea—Carmustine—hematologic cancer	1.09e-05	0.000173	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—hematologic cancer	1.08e-05	0.000173	CcSEcCtD
Afatinib—Vomiting—Irinotecan—hematologic cancer	1.08e-05	0.000172	CcSEcCtD
Afatinib—Vomiting—Mitoxantrone—hematologic cancer	1.08e-05	0.000172	CcSEcCtD
Afatinib—Nausea—Alitretinoin—hematologic cancer	1.08e-05	0.000172	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—hematologic cancer	1.07e-05	0.000171	CcSEcCtD
Afatinib—Rash—Irinotecan—hematologic cancer	1.07e-05	0.000171	CcSEcCtD
Afatinib—Rash—Mitoxantrone—hematologic cancer	1.07e-05	0.000171	CcSEcCtD
Afatinib—Dermatitis—Irinotecan—hematologic cancer	1.07e-05	0.000171	CcSEcCtD
Afatinib—Dermatitis—Mitoxantrone—hematologic cancer	1.07e-05	0.000171	CcSEcCtD
Afatinib—Headache—Irinotecan—hematologic cancer	1.06e-05	0.00017	CcSEcCtD
Afatinib—Headache—Mitoxantrone—hematologic cancer	1.06e-05	0.00017	CcSEcCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	1.06e-05	0.00721	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	1.06e-05	0.00721	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	1.06e-05	0.00721	CbGdCrCtD
Afatinib—Nausea—Ifosfamide—hematologic cancer	1.06e-05	0.00017	CcSEcCtD
Afatinib—Diarrhoea—Cisplatin—hematologic cancer	1.06e-05	0.000168	CcSEcCtD
Afatinib—Alopecia—Methotrexate—hematologic cancer	1.05e-05	0.000168	CcSEcCtD
Afatinib—Vomiting—Gemcitabine—hematologic cancer	1.05e-05	0.000168	CcSEcCtD
Afatinib—Insomnia—Dexamethasone—hematologic cancer	1.05e-05	0.000168	CcSEcCtD
Afatinib—Insomnia—Betamethasone—hematologic cancer	1.05e-05	0.000168	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.05e-05	0.000167	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—hematologic cancer	1.04e-05	0.000167	CcSEcCtD
Afatinib—Rash—Gemcitabine—hematologic cancer	1.04e-05	0.000167	CcSEcCtD
Afatinib—Dermatitis—Gemcitabine—hematologic cancer	1.04e-05	0.000166	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—hematologic cancer	1.04e-05	0.000166	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—hematologic cancer	1.04e-05	0.000166	CcSEcCtD
Afatinib—Headache—Gemcitabine—hematologic cancer	1.04e-05	0.000165	CcSEcCtD
Afatinib—Nausea—Vincristine—hematologic cancer	1.04e-05	0.000165	CcSEcCtD
Afatinib—Dyspepsia—Betamethasone—hematologic cancer	1.02e-05	0.000163	CcSEcCtD
Afatinib—Dyspepsia—Dexamethasone—hematologic cancer	1.02e-05	0.000163	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—hematologic cancer	1.02e-05	0.000163	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—hematologic cancer	1.02e-05	0.000162	CcSEcCtD
Afatinib—Asthenia—Etoposide—hematologic cancer	1.01e-05	0.000162	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—hematologic cancer	1.01e-05	0.000162	CcSEcCtD
Afatinib—Body temperature increased—Triamcinolone—hematologic cancer	1.01e-05	0.000162	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—hematologic cancer	1.01e-05	0.000161	CcSEcCtD
Afatinib—Decreased appetite—Betamethasone—hematologic cancer	1.01e-05	0.000161	CcSEcCtD
Afatinib—Decreased appetite—Dexamethasone—hematologic cancer	1.01e-05	0.000161	CcSEcCtD
Afatinib—Nausea—Irinotecan—hematologic cancer	1.01e-05	0.000161	CcSEcCtD
Afatinib—Nausea—Mitoxantrone—hematologic cancer	1.01e-05	0.000161	CcSEcCtD
Afatinib—Infection—Prednisone—hematologic cancer	1.01e-05	0.000161	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—hematologic cancer	1e-05	0.00016	CcSEcCtD
Afatinib—Gastrointestinal disorder—Betamethasone—hematologic cancer	1e-05	0.00016	CcSEcCtD
Afatinib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1e-05	0.00016	CcSEcCtD
Afatinib—Back pain—Methotrexate—hematologic cancer	1e-05	0.00016	CcSEcCtD
Afatinib—Fatigue—Dexamethasone—hematologic cancer	1e-05	0.00016	CcSEcCtD
Afatinib—Fatigue—Betamethasone—hematologic cancer	1e-05	0.00016	CcSEcCtD
Afatinib—Pruritus—Etoposide—hematologic cancer	1e-05	0.00016	CcSEcCtD
Afatinib—Nervous system disorder—Prednisone—hematologic cancer	9.93e-06	0.000159	CcSEcCtD
Afatinib—Alopecia—Epirubicin—hematologic cancer	9.85e-06	0.000157	CcSEcCtD
Afatinib—Skin disorder—Prednisone—hematologic cancer	9.84e-06	0.000157	CcSEcCtD
Afatinib—Nausea—Gemcitabine—hematologic cancer	9.83e-06	0.000157	CcSEcCtD
Afatinib—Vomiting—Cisplatin—hematologic cancer	9.81e-06	0.000157	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—hematologic cancer	9.77e-06	0.000156	CcSEcCtD
Afatinib—Rash—Cisplatin—hematologic cancer	9.73e-06	0.000155	CcSEcCtD
Afatinib—Dermatitis—Cisplatin—hematologic cancer	9.72e-06	0.000155	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—hematologic cancer	9.71e-06	0.000155	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—hematologic cancer	9.67e-06	0.000154	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—hematologic cancer	9.64e-06	0.000154	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—hematologic cancer	9.51e-06	0.000152	CcSEcCtD
Afatinib—Back pain—Epirubicin—hematologic cancer	9.39e-06	0.00015	CcSEcCtD
Afatinib—Dizziness—Etoposide—hematologic cancer	9.35e-06	0.000149	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—hematologic cancer	9.33e-06	0.000149	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—hematologic cancer	9.3e-06	0.000148	CcSEcCtD
Afatinib—Dizziness—Prednisolone—hematologic cancer	9.22e-06	0.000147	CcSEcCtD
Afatinib—Asthenia—Triamcinolone—hematologic cancer	9.2e-06	0.000147	CcSEcCtD
Afatinib—Body temperature increased—Dexamethasone—hematologic cancer	9.2e-06	0.000147	CcSEcCtD
Afatinib—Body temperature increased—Betamethasone—hematologic cancer	9.2e-06	0.000147	CcSEcCtD
Afatinib—Nausea—Cisplatin—hematologic cancer	9.16e-06	0.000146	CcSEcCtD
Afatinib—Insomnia—Prednisone—hematologic cancer	9.16e-06	0.000146	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—hematologic cancer	9.12e-06	0.000146	CcSEcCtD
Afatinib—Pruritus—Triamcinolone—hematologic cancer	9.07e-06	0.000145	CcSEcCtD
Afatinib—Cough—Methotrexate—hematologic cancer	9.05e-06	0.000144	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—hematologic cancer	9.04e-06	0.000144	CcSEcCtD
Afatinib—Vomiting—Etoposide—hematologic cancer	8.99e-06	0.000143	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—hematologic cancer	8.98e-06	0.000143	CcSEcCtD
Afatinib—Dyspepsia—Prednisone—hematologic cancer	8.92e-06	0.000142	CcSEcCtD
Afatinib—Rash—Etoposide—hematologic cancer	8.91e-06	0.000142	CcSEcCtD
Afatinib—Dermatitis—Etoposide—hematologic cancer	8.9e-06	0.000142	CcSEcCtD
Afatinib—Headache—Etoposide—hematologic cancer	8.85e-06	0.000141	CcSEcCtD
Afatinib—Decreased appetite—Prednisone—hematologic cancer	8.81e-06	0.000141	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—hematologic cancer	8.8e-06	0.00014	CcSEcCtD
Afatinib—Rash—Prednisolone—hematologic cancer	8.79e-06	0.00014	CcSEcCtD
Afatinib—Dermatitis—Prednisolone—hematologic cancer	8.78e-06	0.00014	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	8.77e-06	0.00014	CcSEcCtD
Afatinib—Fatigue—Prednisone—hematologic cancer	8.73e-06	0.000139	CcSEcCtD
Afatinib—Headache—Prednisolone—hematologic cancer	8.73e-06	0.000139	CcSEcCtD
Afatinib—Back pain—Doxorubicin—hematologic cancer	8.69e-06	0.000139	CcSEcCtD
Afatinib—Constipation—Prednisone—hematologic cancer	8.66e-06	0.000138	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—hematologic cancer	8.64e-06	0.000138	CcSEcCtD
Afatinib—Dizziness—Triamcinolone—hematologic cancer	8.48e-06	0.000135	CcSEcCtD
Afatinib—Cough—Epirubicin—hematologic cancer	8.47e-06	0.000135	CcSEcCtD
Afatinib—Infection—Methotrexate—hematologic cancer	8.41e-06	0.000134	CcSEcCtD
Afatinib—Nausea—Etoposide—hematologic cancer	8.39e-06	0.000134	CcSEcCtD
Afatinib—Asthenia—Dexamethasone—hematologic cancer	8.35e-06	0.000133	CcSEcCtD
Afatinib—Asthenia—Betamethasone—hematologic cancer	8.35e-06	0.000133	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—hematologic cancer	8.3e-06	0.000132	CcSEcCtD
Afatinib—Nausea—Prednisolone—hematologic cancer	8.28e-06	0.000132	CcSEcCtD
Afatinib—Pruritus—Dexamethasone—hematologic cancer	8.23e-06	0.000131	CcSEcCtD
Afatinib—Pruritus—Betamethasone—hematologic cancer	8.23e-06	0.000131	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—hematologic cancer	8.22e-06	0.000131	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	8.21e-06	0.000131	CcSEcCtD
Afatinib—Vomiting—Triamcinolone—hematologic cancer	8.15e-06	0.00013	CcSEcCtD
Afatinib—Rash—Triamcinolone—hematologic cancer	8.08e-06	0.000129	CcSEcCtD
Afatinib—Dermatitis—Triamcinolone—hematologic cancer	8.08e-06	0.000129	CcSEcCtD
Afatinib—Headache—Triamcinolone—hematologic cancer	8.03e-06	0.000128	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—hematologic cancer	8.01e-06	0.000128	CcSEcCtD
Afatinib—Diarrhoea—Dexamethasone—hematologic cancer	7.96e-06	0.000127	CcSEcCtD
Afatinib—Diarrhoea—Betamethasone—hematologic cancer	7.96e-06	0.000127	CcSEcCtD
Afatinib—Infection—Epirubicin—hematologic cancer	7.87e-06	0.000126	CcSEcCtD
Afatinib—Cough—Doxorubicin—hematologic cancer	7.84e-06	0.000125	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—hematologic cancer	7.77e-06	0.000124	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—hematologic cancer	7.7e-06	0.000123	CcSEcCtD
Afatinib—Dizziness—Betamethasone—hematologic cancer	7.69e-06	0.000123	CcSEcCtD
Afatinib—Dizziness—Dexamethasone—hematologic cancer	7.69e-06	0.000123	CcSEcCtD
Afatinib—Insomnia—Methotrexate—hematologic cancer	7.66e-06	0.000122	CcSEcCtD
Afatinib—Nausea—Triamcinolone—hematologic cancer	7.61e-06	0.000122	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	7.59e-06	0.000121	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—hematologic cancer	7.55e-06	0.00012	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—hematologic cancer	7.45e-06	0.000119	CcSEcCtD
Afatinib—Vomiting—Betamethasone—hematologic cancer	7.4e-06	0.000118	CcSEcCtD
Afatinib—Vomiting—Dexamethasone—hematologic cancer	7.4e-06	0.000118	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—hematologic cancer	7.36e-06	0.000117	CcSEcCtD
Afatinib—Rash—Betamethasone—hematologic cancer	7.33e-06	0.000117	CcSEcCtD
Afatinib—Rash—Dexamethasone—hematologic cancer	7.33e-06	0.000117	CcSEcCtD
Afatinib—Dermatitis—Betamethasone—hematologic cancer	7.33e-06	0.000117	CcSEcCtD
Afatinib—Dermatitis—Dexamethasone—hematologic cancer	7.33e-06	0.000117	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	7.31e-06	0.000117	CcSEcCtD
Afatinib—Fatigue—Methotrexate—hematologic cancer	7.3e-06	0.000116	CcSEcCtD
Afatinib—Headache—Dexamethasone—hematologic cancer	7.29e-06	0.000116	CcSEcCtD
Afatinib—Headache—Betamethasone—hematologic cancer	7.29e-06	0.000116	CcSEcCtD
Afatinib—Infection—Doxorubicin—hematologic cancer	7.28e-06	0.000116	CcSEcCtD
Afatinib—Asthenia—Prednisone—hematologic cancer	7.27e-06	0.000116	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—hematologic cancer	7.19e-06	0.000115	CcSEcCtD
Afatinib—Pruritus—Prednisone—hematologic cancer	7.17e-06	0.000114	CcSEcCtD
Afatinib—Insomnia—Epirubicin—hematologic cancer	7.17e-06	0.000114	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Betamethasone—hematologic cancer	7.16e-06	0.00485	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Dexamethasone—hematologic cancer	7.16e-06	0.00485	CbGdCrCtD
Afatinib—Skin disorder—Doxorubicin—hematologic cancer	7.12e-06	0.000114	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—hematologic cancer	7.06e-06	0.000113	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—hematologic cancer	6.97e-06	0.000111	CcSEcCtD
Afatinib—Diarrhoea—Prednisone—hematologic cancer	6.93e-06	0.000111	CcSEcCtD
Afatinib—Nausea—Betamethasone—hematologic cancer	6.91e-06	0.00011	CcSEcCtD
Afatinib—Nausea—Dexamethasone—hematologic cancer	6.91e-06	0.00011	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—hematologic cancer	6.89e-06	0.00011	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.84e-06	0.000109	CcSEcCtD
Afatinib—Fatigue—Epirubicin—hematologic cancer	6.83e-06	0.000109	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Betamethasone—hematologic cancer	6.8e-06	0.00461	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Dexamethasone—hematologic cancer	6.8e-06	0.00461	CbGdCrCtD
Afatinib—Constipation—Epirubicin—hematologic cancer	6.77e-06	0.000108	CcSEcCtD
Afatinib—Dizziness—Prednisone—hematologic cancer	6.7e-06	0.000107	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—hematologic cancer	6.69e-06	0.000107	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Triamcinolone—hematologic cancer	6.64e-06	0.0045	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—hematologic cancer	6.64e-06	0.0045	CbGdCrCtD
Afatinib—Insomnia—Doxorubicin—hematologic cancer	6.63e-06	0.000106	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—hematologic cancer	6.54e-06	0.000104	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Prednisolone—hematologic cancer	6.48e-06	0.00439	CbGdCrCtD
Afatinib—Dyspepsia—Doxorubicin—hematologic cancer	6.45e-06	0.000103	CcSEcCtD
Afatinib—Vomiting—Prednisone—hematologic cancer	6.44e-06	0.000103	CcSEcCtD
Afatinib—Rash—Prednisone—hematologic cancer	6.39e-06	0.000102	CcSEcCtD
Afatinib—Dermatitis—Prednisone—hematologic cancer	6.38e-06	0.000102	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—hematologic cancer	6.37e-06	0.000102	CcSEcCtD
Afatinib—Headache—Prednisone—hematologic cancer	6.35e-06	0.000101	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.33e-06	0.000101	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—hematologic cancer	6.32e-06	0.000101	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisone—hematologic cancer	6.3e-06	0.00427	CbGdCrCtD
Afatinib—Constipation—Doxorubicin—hematologic cancer	6.27e-06	0.0001	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—hematologic cancer	6.26e-06	0.0001	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisolone—hematologic cancer	6.15e-06	0.00417	CbGdCrCtD
Afatinib—Asthenia—Methotrexate—hematologic cancer	6.07e-06	9.69e-05	CcSEcCtD
Afatinib—Nausea—Prednisone—hematologic cancer	6.02e-06	9.6e-05	CcSEcCtD
Afatinib—Pruritus—Methotrexate—hematologic cancer	5.99e-06	9.56e-05	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—hematologic cancer	5.79e-06	9.25e-05	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—hematologic cancer	5.79e-06	9.24e-05	CcSEcCtD
Afatinib—Asthenia—Epirubicin—hematologic cancer	5.68e-06	9.07e-05	CcSEcCtD
Afatinib—Pruritus—Epirubicin—hematologic cancer	5.61e-06	8.95e-05	CcSEcCtD
Afatinib—Dizziness—Methotrexate—hematologic cancer	5.6e-06	8.93e-05	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—hematologic cancer	5.42e-06	8.65e-05	CcSEcCtD
Afatinib—Vomiting—Methotrexate—hematologic cancer	5.38e-06	8.59e-05	CcSEcCtD
Afatinib—Rash—Methotrexate—hematologic cancer	5.34e-06	8.52e-05	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—hematologic cancer	5.33e-06	8.51e-05	CcSEcCtD
Afatinib—Headache—Methotrexate—hematologic cancer	5.3e-06	8.46e-05	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—hematologic cancer	5.26e-06	8.39e-05	CcSEcCtD
Afatinib—Dizziness—Epirubicin—hematologic cancer	5.24e-06	8.36e-05	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—hematologic cancer	5.19e-06	8.28e-05	CcSEcCtD
Afatinib—Vomiting—Epirubicin—hematologic cancer	5.04e-06	8.04e-05	CcSEcCtD
Afatinib—Nausea—Methotrexate—hematologic cancer	5.03e-06	8.03e-05	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—hematologic cancer	5.02e-06	8e-05	CcSEcCtD
Afatinib—Rash—Epirubicin—hematologic cancer	5e-06	7.97e-05	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—hematologic cancer	4.99e-06	7.96e-05	CcSEcCtD
Afatinib—Headache—Epirubicin—hematologic cancer	4.96e-06	7.92e-05	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—hematologic cancer	4.85e-06	7.74e-05	CcSEcCtD
Afatinib—Nausea—Epirubicin—hematologic cancer	4.71e-06	7.51e-05	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—hematologic cancer	4.66e-06	7.44e-05	CcSEcCtD
Afatinib—Rash—Doxorubicin—hematologic cancer	4.62e-06	7.38e-05	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—hematologic cancer	4.62e-06	7.37e-05	CcSEcCtD
Afatinib—Headache—Doxorubicin—hematologic cancer	4.59e-06	7.33e-05	CcSEcCtD
Afatinib—Nausea—Doxorubicin—hematologic cancer	4.35e-06	6.95e-05	CcSEcCtD
Afatinib—EGFR—Disease—MTOR—hematologic cancer	4.14e-07	6.54e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—hematologic cancer	4.14e-07	6.54e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—hematologic cancer	4.13e-07	6.53e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—hematologic cancer	4.13e-07	6.53e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TSC2—hematologic cancer	4.13e-07	6.53e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR3—hematologic cancer	4.12e-07	6.51e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—hematologic cancer	4.12e-07	6.51e-06	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—hematologic cancer	4.1e-07	6.49e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MDM2—hematologic cancer	4.1e-07	6.48e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—hematologic cancer	4.09e-07	6.46e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK14—hematologic cancer	4.08e-07	6.45e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1B—hematologic cancer	4.07e-07	6.43e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1B—hematologic cancer	4.06e-07	6.41e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—hematologic cancer	4.06e-07	6.41e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—hematologic cancer	4.05e-07	6.4e-06	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—hematologic cancer	4.02e-07	6.35e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NQO1—hematologic cancer	4.01e-07	6.34e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CD44—hematologic cancer	4.01e-07	6.34e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—hematologic cancer	4.01e-07	6.33e-06	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—hematologic cancer	4.01e-07	6.33e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—hematologic cancer	4e-07	6.33e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—hematologic cancer	3.99e-07	6.31e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MTOR—hematologic cancer	3.99e-07	6.31e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—hematologic cancer	3.99e-07	6.3e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—hematologic cancer	3.98e-07	6.3e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—hematologic cancer	3.98e-07	6.3e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—hematologic cancer	3.98e-07	6.29e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—hematologic cancer	3.98e-07	6.29e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR3—hematologic cancer	3.97e-07	6.28e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—hematologic cancer	3.97e-07	6.27e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FN1—hematologic cancer	3.95e-07	6.25e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK14—hematologic cancer	3.93e-07	6.22e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—hematologic cancer	3.92e-07	6.2e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CREBBP—hematologic cancer	3.92e-07	6.19e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKBIA—hematologic cancer	3.91e-07	6.18e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BAD—hematologic cancer	3.91e-07	6.18e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—hematologic cancer	3.89e-07	6.14e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—hematologic cancer	3.88e-07	6.14e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—hematologic cancer	3.88e-07	6.14e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—hematologic cancer	3.87e-07	6.13e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK3—hematologic cancer	3.87e-07	6.12e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—hematologic cancer	3.87e-07	6.12e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—hematologic cancer	3.87e-07	6.12e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—hematologic cancer	3.86e-07	6.1e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—hematologic cancer	3.86e-07	6.1e-06	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—hematologic cancer	3.83e-07	6.06e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FN1—hematologic cancer	3.81e-07	6.02e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYCS—hematologic cancer	3.8e-07	6e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK8—hematologic cancer	3.79e-07	5.99e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CD80—hematologic cancer	3.79e-07	5.99e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—hematologic cancer	3.78e-07	5.98e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—hematologic cancer	3.78e-07	5.98e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—hematologic cancer	3.78e-07	5.98e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—hematologic cancer	3.78e-07	5.98e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HSP90AA1—hematologic cancer	3.77e-07	5.96e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKBIA—hematologic cancer	3.77e-07	5.95e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BAD—hematologic cancer	3.77e-07	5.95e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—hematologic cancer	3.76e-07	5.94e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—hematologic cancer	3.75e-07	5.92e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—hematologic cancer	3.74e-07	5.92e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—hematologic cancer	3.74e-07	5.92e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—hematologic cancer	3.73e-07	5.9e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—hematologic cancer	3.73e-07	5.89e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTPN11—hematologic cancer	3.72e-07	5.88e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—hematologic cancer	3.71e-07	5.87e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—EP300—hematologic cancer	3.7e-07	5.84e-06	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—hematologic cancer	3.69e-07	5.84e-06	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—hematologic cancer	3.68e-07	5.82e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—hematologic cancer	3.67e-07	5.8e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK8—hematologic cancer	3.67e-07	5.79e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—hematologic cancer	3.66e-07	5.78e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK8—hematologic cancer	3.65e-07	5.77e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CD80—hematologic cancer	3.65e-07	5.77e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—hematologic cancer	3.65e-07	5.76e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—hematologic cancer	3.65e-07	5.76e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK3—hematologic cancer	3.62e-07	5.73e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—hematologic cancer	3.62e-07	5.72e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CREB1—hematologic cancer	3.6e-07	5.69e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—hematologic cancer	3.6e-07	5.69e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—hematologic cancer	3.59e-07	5.68e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—hematologic cancer	3.59e-07	5.67e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTPN11—hematologic cancer	3.58e-07	5.66e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—hematologic cancer	3.58e-07	5.66e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EP300—hematologic cancer	3.57e-07	5.65e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—EP300—hematologic cancer	3.56e-07	5.63e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—hematologic cancer	3.56e-07	5.62e-06	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—hematologic cancer	3.55e-07	5.61e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—hematologic cancer	3.54e-07	5.59e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—hematologic cancer	3.52e-07	5.57e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6R—hematologic cancer	3.51e-07	5.55e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CREBBP—hematologic cancer	3.51e-07	5.55e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3R1—hematologic cancer	3.51e-07	5.54e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—hematologic cancer	3.48e-07	5.51e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—hematologic cancer	3.48e-07	5.5e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—hematologic cancer	3.47e-07	5.49e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CREB1—hematologic cancer	3.47e-07	5.49e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—hematologic cancer	3.47e-07	5.48e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—hematologic cancer	3.46e-07	5.47e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—hematologic cancer	3.46e-07	5.46e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—hematologic cancer	3.46e-07	5.46e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—hematologic cancer	3.45e-07	5.45e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—hematologic cancer	3.43e-07	5.42e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—EP300—hematologic cancer	3.41e-07	5.39e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—hematologic cancer	3.4e-07	5.37e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6R—hematologic cancer	3.39e-07	5.35e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—hematologic cancer	3.38e-07	5.35e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—hematologic cancer	3.38e-07	5.35e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CREBBP—hematologic cancer	3.38e-07	5.34e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—hematologic cancer	3.35e-07	5.3e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAP2K1—hematologic cancer	3.35e-07	5.29e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—hematologic cancer	3.35e-07	5.29e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—hematologic cancer	3.34e-07	5.28e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—hematologic cancer	3.34e-07	5.28e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—hematologic cancer	3.34e-07	5.28e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—hematologic cancer	3.33e-07	5.27e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—hematologic cancer	3.33e-07	5.27e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—hematologic cancer	3.33e-07	5.26e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—hematologic cancer	3.32e-07	5.24e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK3—hematologic cancer	3.31e-07	5.23e-06	CbGpPWpGaD
Afatinib—LCK—Disease—EP300—hematologic cancer	3.29e-07	5.2e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—hematologic cancer	3.26e-07	5.15e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—hematologic cancer	3.24e-07	5.12e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—hematologic cancer	3.24e-07	5.12e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAP2K1—hematologic cancer	3.23e-07	5.1e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—hematologic cancer	3.21e-07	5.07e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK3—hematologic cancer	3.2e-07	5.06e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—hematologic cancer	3.2e-07	5.06e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—hematologic cancer	3.2e-07	5.06e-06	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—hematologic cancer	3.2e-07	5.05e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—hematologic cancer	3.19e-07	5.05e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK3—hematologic cancer	3.19e-07	5.04e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—hematologic cancer	3.19e-07	5.04e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGF2—hematologic cancer	3.18e-07	5.03e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3R1—hematologic cancer	3.14e-07	4.97e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—hematologic cancer	3.11e-07	4.92e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—hematologic cancer	3.11e-07	4.91e-06	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—hematologic cancer	3.08e-07	4.87e-06	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—hematologic cancer	3.08e-07	4.86e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NCOR1—hematologic cancer	3.08e-07	4.86e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—hematologic cancer	3.08e-07	4.86e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGF2—hematologic cancer	3.07e-07	4.85e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK3—hematologic cancer	3.06e-07	4.83e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JAK2—hematologic cancer	3.05e-07	4.83e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3R1—hematologic cancer	3.03e-07	4.78e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—hematologic cancer	2.99e-07	4.73e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—hematologic cancer	2.99e-07	4.72e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—hematologic cancer	2.98e-07	4.71e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—hematologic cancer	2.98e-07	4.7e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—hematologic cancer	2.97e-07	4.7e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—hematologic cancer	2.97e-07	4.69e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—hematologic cancer	2.96e-07	4.68e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK3—hematologic cancer	2.95e-07	4.66e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—hematologic cancer	2.94e-07	4.65e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JAK2—hematologic cancer	2.94e-07	4.65e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—hematologic cancer	2.9e-07	4.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MTOR—hematologic cancer	2.9e-07	4.58e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—hematologic cancer	2.88e-07	4.55e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—hematologic cancer	2.87e-07	4.54e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—hematologic cancer	2.87e-07	4.53e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—hematologic cancer	2.87e-07	4.53e-06	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—hematologic cancer	2.86e-07	4.52e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—hematologic cancer	2.83e-07	4.48e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—hematologic cancer	2.8e-07	4.42e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—hematologic cancer	2.79e-07	4.42e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MTOR—hematologic cancer	2.79e-07	4.42e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—hematologic cancer	2.77e-07	4.38e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—hematologic cancer	2.75e-07	4.34e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—hematologic cancer	2.73e-07	4.32e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—hematologic cancer	2.72e-07	4.3e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—hematologic cancer	2.72e-07	4.3e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—EP300—hematologic cancer	2.67e-07	4.22e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—hematologic cancer	2.67e-07	4.22e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—hematologic cancer	2.66e-07	4.21e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—hematologic cancer	2.65e-07	4.19e-06	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—hematologic cancer	2.65e-07	4.18e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—hematologic cancer	2.64e-07	4.18e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—hematologic cancer	2.63e-07	4.16e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—hematologic cancer	2.62e-07	4.14e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—hematologic cancer	2.61e-07	4.13e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—hematologic cancer	2.6e-07	4.1e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—hematologic cancer	2.59e-07	4.09e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—hematologic cancer	2.57e-07	4.06e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—hematologic cancer	2.57e-07	4.06e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—hematologic cancer	2.56e-07	4.04e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—hematologic cancer	2.53e-07	4e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—hematologic cancer	2.52e-07	3.99e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—hematologic cancer	2.51e-07	3.97e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—hematologic cancer	2.51e-07	3.96e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—hematologic cancer	2.5e-07	3.95e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—hematologic cancer	2.5e-07	3.95e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK8—hematologic cancer	2.45e-07	3.87e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—hematologic cancer	2.45e-07	3.87e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—hematologic cancer	2.44e-07	3.86e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—hematologic cancer	2.44e-07	3.85e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—hematologic cancer	2.43e-07	3.84e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—hematologic cancer	2.42e-07	3.83e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—hematologic cancer	2.42e-07	3.83e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—hematologic cancer	2.41e-07	3.82e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EP300—hematologic cancer	2.39e-07	3.78e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK8—hematologic cancer	2.36e-07	3.73e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—hematologic cancer	2.34e-07	3.7e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—hematologic cancer	2.34e-07	3.69e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—hematologic cancer	2.33e-07	3.69e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—hematologic cancer	2.32e-07	3.67e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EP300—hematologic cancer	2.3e-07	3.64e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.28e-07	3.61e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—hematologic cancer	2.26e-07	3.58e-06	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—hematologic cancer	2.25e-07	3.56e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—hematologic cancer	2.24e-07	3.54e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—hematologic cancer	2.24e-07	3.54e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—hematologic cancer	2.24e-07	3.53e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—hematologic cancer	2.23e-07	3.53e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—hematologic cancer	2.23e-07	3.53e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—hematologic cancer	2.18e-07	3.45e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—hematologic cancer	2.16e-07	3.41e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—hematologic cancer	2.16e-07	3.41e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—hematologic cancer	2.15e-07	3.4e-06	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—hematologic cancer	2.15e-07	3.4e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—hematologic cancer	2.15e-07	3.4e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK3—hematologic cancer	2.14e-07	3.38e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CREBBP—hematologic cancer	2.12e-07	3.35e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—hematologic cancer	2.08e-07	3.29e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—hematologic cancer	2.08e-07	3.28e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK3—hematologic cancer	2.06e-07	3.26e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—hematologic cancer	2.06e-07	3.26e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.01e-07	3.17e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—hematologic cancer	2.01e-07	3.17e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—hematologic cancer	2e-07	3.16e-06	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—hematologic cancer	1.99e-07	3.14e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—hematologic cancer	1.98e-07	3.13e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—hematologic cancer	1.97e-07	3.12e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—hematologic cancer	1.92e-07	3.04e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.9e-07	3e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—hematologic cancer	1.85e-07	2.93e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—hematologic cancer	1.77e-07	2.79e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.75e-07	2.77e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—hematologic cancer	1.71e-07	2.7e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—hematologic cancer	1.7e-07	2.69e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—hematologic cancer	1.65e-07	2.6e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—hematologic cancer	1.64e-07	2.58e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—hematologic cancer	1.61e-07	2.55e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—hematologic cancer	1.58e-07	2.49e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—hematologic cancer	1.57e-07	2.47e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—hematologic cancer	1.51e-07	2.39e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—hematologic cancer	1.51e-07	2.38e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—hematologic cancer	1.44e-07	2.28e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—EP300—hematologic cancer	1.44e-07	2.28e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—hematologic cancer	1.39e-07	2.2e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.07e-07	1.69e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—hematologic cancer	8.72e-08	1.38e-06	CbGpPWpGaD
